MX366197B - Metodo de monitoreo terapeutico de farmacos depuradores de nitrogeno. - Google Patents
Metodo de monitoreo terapeutico de farmacos depuradores de nitrogeno.Info
- Publication number
- MX366197B MX366197B MX2014003854A MX2014003854A MX366197B MX 366197 B MX366197 B MX 366197B MX 2014003854 A MX2014003854 A MX 2014003854A MX 2014003854 A MX2014003854 A MX 2014003854A MX 366197 B MX366197 B MX 366197B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- nitrogen scavenging
- therapeutic monitoring
- nitrogen
- scavenging drugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
- G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
- G01N31/221—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators for investigating pH value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/17—Nitrogen containing
- Y10T436/173845—Amine and quaternary ammonium
- Y10T436/175383—Ammonia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Ecology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
Abstract
La presente invención se refiere a métodos para evaluar la exposición de amoníaco diario con base en una medición única del nivel en sangre de amoníaco en ayunas, así como también métodos que utilizan esta técnica para ajustar la dosificación de un fármaco depurador de nitrógeno, determinar ya sea administrar un fármaco depurador de nitrógeno, y tratar trastornos de retención de nitrógeno.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161542100P | 2011-09-30 | 2011-09-30 | |
US201161564668P | 2011-11-29 | 2011-11-29 | |
PCT/US2012/028620 WO2013048558A2 (en) | 2011-09-30 | 2012-03-09 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014003854A MX2014003854A (es) | 2014-10-17 |
MX366197B true MX366197B (es) | 2019-06-25 |
Family
ID=47892277
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014003854A MX366197B (es) | 2011-09-30 | 2012-03-09 | Metodo de monitoreo terapeutico de farmacos depuradores de nitrogeno. |
MX2019006900A MX2019006900A (es) | 2011-09-30 | 2014-03-28 | Metodos de monitoreo terapeutico de farmacos depuradores de nitrogeno. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019006900A MX2019006900A (es) | 2011-09-30 | 2014-03-28 | Metodos de monitoreo terapeutico de farmacos depuradores de nitrogeno. |
Country Status (24)
Country | Link |
---|---|
US (21) | US8404215B1 (es) |
EP (2) | EP2760479B1 (es) |
JP (2) | JP6073898B2 (es) |
KR (2) | KR102019000B1 (es) |
CN (2) | CN107271696A (es) |
AU (2) | AU2012316750B2 (es) |
BR (1) | BR112014007357B1 (es) |
CA (1) | CA2850391A1 (es) |
CL (1) | CL2014000783A1 (es) |
CY (1) | CY1119028T1 (es) |
DK (1) | DK2760479T3 (es) |
ES (1) | ES2629859T3 (es) |
HR (1) | HRP20171063T1 (es) |
HU (1) | HUE035220T2 (es) |
IL (2) | IL231732A (es) |
LT (1) | LT2760479T (es) |
MX (2) | MX366197B (es) |
PL (1) | PL2760479T3 (es) |
PT (1) | PT2760479T (es) |
RS (1) | RS56196B1 (es) |
SG (1) | SG11201400781TA (es) |
SI (1) | SI2760479T1 (es) |
WO (1) | WO2013048558A2 (es) |
ZA (1) | ZA201401851B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2760479T3 (pl) | 2011-09-30 | 2017-09-29 | Horizon Therapeutics, Llc | Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu |
EP3222275B1 (en) | 2012-04-20 | 2020-06-24 | Immedica Pharma AB | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
CA2891657A1 (en) * | 2012-11-21 | 2014-05-30 | Bruce Scharschmidt | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
US20150094278A1 (en) * | 2013-09-30 | 2015-04-02 | Hyperion Therapeutics, Inc. | Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy |
WO2015057747A1 (en) * | 2013-10-14 | 2015-04-23 | Hyperion Therapeutics, Inc. | Methods of treating urea cycle disorders |
CN105764497A (zh) | 2013-11-14 | 2016-07-13 | 奥特吉尼克斯制药公司 | 三酸甘油酯的固体组合物及其用途 |
EP3137116B1 (en) | 2014-04-30 | 2020-12-16 | The Johns Hopkins University | Dendrimer compositions and their use in treatment of diseases of the eye |
ES2748294T3 (es) * | 2014-06-04 | 2020-03-16 | Immedica Pharma Ab | Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre |
EP3180031A1 (en) | 2014-08-13 | 2017-06-21 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
CN108430514B (zh) | 2015-10-29 | 2023-11-03 | 约翰霍普金斯大学 | 用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法 |
WO2017147193A1 (en) * | 2016-02-22 | 2017-08-31 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
US9914692B2 (en) * | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
JP6752748B2 (ja) | 2017-03-30 | 2020-09-09 | 住友重機械工業株式会社 | 減速装置 |
EP3649474A1 (en) * | 2017-07-03 | 2020-05-13 | Abbott Laboratories | Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood |
CA3071387A1 (en) * | 2017-08-22 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating urea cycle disorders by interfering with glucagon receptor signaling |
US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
CN115103690A (zh) | 2019-12-04 | 2022-09-23 | 阿什瓦塔治疗股份有限公司 | 用于将药物递送至眼的树枝状大分子组合物和方法 |
WO2022011061A1 (en) * | 2020-07-07 | 2022-01-13 | Acer Therapeutics Inc. | Methods of administering taste masked phenylbutyrate and compositions therefor |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1004595A (en) | 1911-05-25 | 1911-10-03 | Sargents Sons Corp C G | Carrier for washing-bowls. |
US1018300A (en) | 1911-06-12 | 1912-02-20 | John Davidson | Condensing steam-engine. |
US3686238A (en) | 1970-01-19 | 1972-08-22 | Syntex Corp | Glycerol esterified with 2-naphthyl-acetic acids and fatty acids |
US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
US5879657A (en) | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
ATE201013T1 (de) | 1995-02-07 | 2001-05-15 | Brusilow Entpr Llc | Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen |
DE19805854C1 (de) | 1998-02-13 | 1999-05-12 | Claas Usines France | Schalteinrichtung für Schneidmesser |
US6219567B1 (en) * | 1999-06-21 | 2001-04-17 | Cardiox Corporation | Monitoring of total ammoniacal concentration in blood |
IT1317073B1 (it) | 2000-12-12 | 2003-05-26 | Mini Ricerca Scient Tecnolog | Esteri dell'acido fenilbutirrico, procedimenti per la loro produzionee loro impiego terapeutico. |
US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
US6825384B1 (en) | 2004-01-29 | 2004-11-30 | The Nutrasweet Company | Bromine free TEMPO based catalyst system for oxidation of primary and secondary alcohols using NaOCl as an oxidant |
US20050273359A1 (en) | 2004-06-03 | 2005-12-08 | Young David E | System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure |
CN1778963A (zh) * | 2004-11-23 | 2006-05-31 | 苏州艾杰生物科技有限公司 | 血氨含量测定方法及血氨诊断试剂盒 |
EA011716B1 (ru) * | 2004-11-26 | 2009-04-28 | Ю Си Эл БИЗНЕС Пи Эл Си | Композиция, содержащая орнитин и фенилацетат или фенилбутират, для лечения печеночной энцефалопатии |
US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
US20070004805A1 (en) | 2005-07-01 | 2007-01-04 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
WO2007059031A2 (en) | 2005-11-10 | 2007-05-24 | Massachusetts Institute Of Technology | Methods and compositions for raising levels and release of gamma aminobutyric acid |
US8094521B2 (en) | 2007-02-28 | 2012-01-10 | Nightingale Products LLC | Caregiver personal alert device |
CN101959429B (zh) | 2008-01-08 | 2014-09-10 | 阿克塞利亚制药公司 | 抗微生物肽系统的激动剂 |
EP3133396B1 (en) | 2008-04-29 | 2018-09-05 | Horizon Therapeutics, LLC | Methods of treatment using ammonia-scavenging drugs |
WO2009145323A1 (ja) | 2008-05-30 | 2009-12-03 | 日産化学工業株式会社 | 多環式化合物を用いるアルコールの酸化方法 |
EP2338050A1 (en) | 2008-08-29 | 2011-06-29 | Ucyclyd Pharma, Inc. | Dosing and monitoring patients on nitrogen-scavenging drugs |
HUE029912T2 (en) | 2008-08-29 | 2017-03-28 | Horizon Therapeutics Llc | Treatments using an ammonia binding agent |
WO2011011781A1 (en) | 2009-07-24 | 2011-01-27 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
WO2012008228A1 (ja) | 2010-07-16 | 2012-01-19 | 第一三共株式会社 | アルコール類の酸化方法 |
EP2611470B1 (en) | 2010-08-31 | 2017-08-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation |
PL2760479T3 (pl) | 2011-09-30 | 2017-09-29 | Horizon Therapeutics, Llc | Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu |
EP2607366A1 (en) | 2011-12-21 | 2013-06-26 | Lunamed AG | Glycerol phenyl butyrate esters |
EP3222275B1 (en) | 2012-04-20 | 2020-06-24 | Immedica Pharma AB | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
CA2891657A1 (en) | 2012-11-21 | 2014-05-30 | Bruce Scharschmidt | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
CN103304402B (zh) | 2013-05-24 | 2015-04-22 | 苏州诚和医药化学有限公司 | 一种制备4-苯-1-丁酸的方法 |
US20150094278A1 (en) | 2013-09-30 | 2015-04-02 | Hyperion Therapeutics, Inc. | Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy |
WO2015057747A1 (en) | 2013-10-14 | 2015-04-23 | Hyperion Therapeutics, Inc. | Methods of treating urea cycle disorders |
WO2015063659A1 (en) | 2013-10-30 | 2015-05-07 | Lupin Limited | Process for the preparation of glycerol phenylbutyrate |
ES2748294T3 (es) | 2014-06-04 | 2020-03-16 | Immedica Pharma Ab | Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre |
WO2017147193A1 (en) | 2016-02-22 | 2017-08-31 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
US20190076383A1 (en) | 2017-09-08 | 2019-03-14 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders |
US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
-
2012
- 2012-03-09 PL PL12835407T patent/PL2760479T3/pl unknown
- 2012-03-09 PT PT128354073T patent/PT2760479T/pt unknown
- 2012-03-09 AU AU2012316750A patent/AU2012316750B2/en active Active
- 2012-03-09 HU HUE12835407A patent/HUE035220T2/hu unknown
- 2012-03-09 BR BR112014007357-0A patent/BR112014007357B1/pt active IP Right Grant
- 2012-03-09 WO PCT/US2012/028620 patent/WO2013048558A2/en active Application Filing
- 2012-03-09 CN CN201710239760.1A patent/CN107271696A/zh active Pending
- 2012-03-09 LT LTEP12835407.3T patent/LT2760479T/lt unknown
- 2012-03-09 KR KR1020187020761A patent/KR102019000B1/ko active IP Right Grant
- 2012-03-09 KR KR1020147011146A patent/KR20140094517A/ko not_active Application Discontinuation
- 2012-03-09 EP EP12835407.3A patent/EP2760479B1/en active Active
- 2012-03-09 SI SI201230985A patent/SI2760479T1/sl unknown
- 2012-03-09 MX MX2014003854A patent/MX366197B/es active IP Right Grant
- 2012-03-09 SG SG11201400781TA patent/SG11201400781TA/en unknown
- 2012-03-09 CA CA2850391A patent/CA2850391A1/en not_active Withdrawn
- 2012-03-09 EP EP17168773.4A patent/EP3263102A1/en not_active Withdrawn
- 2012-03-09 RS RS20170682A patent/RS56196B1/sr unknown
- 2012-03-09 US US13/417,137 patent/US8404215B1/en active Active
- 2012-03-09 ES ES12835407.3T patent/ES2629859T3/es active Active
- 2012-03-09 CN CN201280048373.5A patent/CN104039358A/zh active Pending
- 2012-03-09 DK DK12835407.3T patent/DK2760479T3/en active
- 2012-03-09 JP JP2014533519A patent/JP6073898B2/ja active Active
-
2013
- 2013-02-22 US US13/775,000 patent/US9095559B2/en active Active
-
2014
- 2014-03-12 ZA ZA2014/01851A patent/ZA201401851B/en unknown
- 2014-03-27 IL IL231732A patent/IL231732A/en active IP Right Grant
- 2014-03-28 CL CL2014000783A patent/CL2014000783A1/es unknown
- 2014-03-28 MX MX2019006900A patent/MX2019006900A/es unknown
-
2015
- 2015-08-03 US US14/816,674 patent/US9254278B2/en active Active
- 2015-12-03 US US14/958,259 patent/US9326966B2/en active Active
-
2016
- 2016-03-18 US US15/074,691 patent/US20160199333A1/en not_active Abandoned
- 2016-03-18 US US15/074,666 patent/US20160202240A1/en not_active Abandoned
- 2016-03-18 US US15/074,625 patent/US20160199332A1/en not_active Abandoned
- 2016-03-18 US US15/074,716 patent/US20160199334A1/en not_active Abandoned
-
2017
- 2017-01-05 JP JP2017000550A patent/JP6425746B2/ja active Active
- 2017-03-13 US US15/457,643 patent/US9999608B2/en active Active
- 2017-06-28 CY CY20171100688T patent/CY1119028T1/el unknown
- 2017-07-11 HR HRP20171063TT patent/HRP20171063T1/hr unknown
- 2017-08-24 IL IL254134A patent/IL254134A0/en unknown
- 2017-08-25 US US15/687,132 patent/US9962359B2/en active Active
- 2017-08-25 US US15/687,118 patent/US9962358B2/en active Active
- 2017-09-08 US US15/699,209 patent/US20180021293A1/en not_active Abandoned
- 2017-10-23 AU AU2017251691A patent/AU2017251691A1/en not_active Abandoned
-
2018
- 2018-04-03 US US15/944,422 patent/US10183003B2/en active Active
- 2018-04-03 US US15/944,432 patent/US10183005B2/en active Active
- 2018-04-03 US US15/944,416 patent/US10045959B1/en active Active
- 2018-04-03 US US15/944,428 patent/US10183004B2/en active Active
- 2018-04-03 US US15/944,398 patent/US10045958B1/en active Active
- 2018-04-03 US US15/944,411 patent/US10183002B2/en active Active
- 2018-05-15 US US15/980,376 patent/US10183006B2/en active Active
- 2018-11-16 US US16/194,061 patent/US10617665B2/en active Active
-
2020
- 2020-03-10 US US16/814,549 patent/US20210000784A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019006900A (es) | Metodos de monitoreo terapeutico de farmacos depuradores de nitrogeno. | |
MX2015002292A (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r. | |
EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
EA201370008A1 (ru) | Лечение когнитивных нарушений | |
EP2726066A4 (en) | DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME | |
PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
CL2014002935A1 (es) | Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador | |
WO2012100043A3 (en) | Controlled release oral pharmaceutical dosage forms comprising mgbg | |
MX2013014849A (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia. | |
MX2016007370A (es) | Agente terapeutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor. | |
MX2014014814A (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
MX368640B (es) | Composición farmacéutica para tratar inflamación y dolor. | |
MX2014014817A (es) | Compuestos para el tratamiento de inflamacion y dolor. | |
NZ629800A (en) | (1r,4r)-6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro-[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for treating fibromyalgia and chronic fatigue syndrome | |
RU2011108787A (ru) | Способ лечения больных красным плоским лишаем слизистой полости рта | |
UA60735U (ru) | Способ оценки адекватности дозы нейропротектора | |
UA106946C2 (uk) | Спосіб оцінки антисекреторної активності омепразолу у гастроентерологічних хворих | |
MX2019009243A (es) | Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa. | |
EA201201208A1 (ru) | Твердая лекарственная форма, обладающая анорексигенным действием (варианты) | |
TN2013000503A1 (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
UA64828U (ru) | Способ медицинской реабилитации взрослых больных с соматизированными расстройствами | |
UA82641U (ru) | Способ лечения нейросифилиса с паренхиматозными изменениями | |
EA201491695A1 (ru) | Лечение рака ингибиторами tor-киназы | |
MY166773A (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
RU2012116674A (ru) | Способ лечения когнитивной дисфункции у больных артериальной гипертонией с метаболическим синдромом |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: HORIZON THERAPEUTICS, LLC |
|
HC | Change of company name or juridical status |
Owner name: HORIZON THERAPEUTICS, LLC |
|
FG | Grant or registration |